The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

A method for activating metabolism for muscle cells involves administering an energy-metabolic activating agent to a human patient, the energy-metabolic activing agent as follows:

(1) a sugar transporter (GLUT4) gene-expression promoting agent, including at least one active substance selected from the following: 5-hydroxy-3,7-dimethoxyflavone; techtochrysin; 3,7,4-trimethylkaempferol; retusine; pentamethyiquercetin; trimethylapigenin; tetramethylkaempferol; and 5, 7-dimethoxyflavone,
(2) a sugar transporter (GLUT4) gene-expression promoting agent, including at least one active substance selected from either techtochrysin or 5,7-dimethoxyflavone, and
(3) a sugar transporter (GLUT4) gene-expression promoting agent within the muscle cells that includes any one of the chemical compounds shown in the following chemical formula 1. (Of such formula 1, R1 and R2, respectively, mean an alkyl group with hydrogen or with 13-carbon.)

##STR00001##

A method for activating metabolism for muscle cells involves administering an energy-metabolic activating agent to a human patient, the energy-metabolic activing agent as follows:

(1) a sugar transporter (GLUT4) gene-expression promoting agent, including at least one active substance selected from the following: 5-hydroxy-3,7-dimethoxyflavone; techtochrysin; 3,7,4-trimethylkaempferol; retusine; pentamethyiquercetin; trimethylapigenin; tetramethylkaempferol; and 5, 7-dimethoxyflavone,
(2) a sugar transporter (GLUT4) gene-expression promoting agent, including at least one active substance selected from either techtochrysin or 5,7-dimethoxyflavone, and
(3) a sugar transporter (GLUT4) gene-expression promoting agent within the muscle cells that includes any one of the chemical compounds shown in the following chemical formula 1. (Of such formula 1, R1 and R2, respectively, mean an alkyl group with hydrogen or with 13-carbon.)

##STR00001##

An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.

An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.

In general, certain embodiments of the present disclosure provide compositions or mechanisms for oral administration of caffeine via a functional nutraceutical confectionary composition. According to various embodiments, a nutraceutical confectionary composition is provided with a ratio of caffeine to L-theanine ranging from about 1:1 to about 1:2. In some embodiments, the ratio of caffeine to L-theanine is about 2:3. In various embodiments, the nutraceutical confectionary composition may provide caffeine in a range from about 5 mg to about 100 mg per serving. L-theanine may be provided in a range from about 5 mg to about 200 mg per serving. In some embodiments, caffeine may comprise about 0.8% to 10% by weight of the composition; and L-theanine may comprise about 1.2% to 20% by weight of the composition. In certain embodiments, the nutraceutical confectionary composition may comprise a chewing gum.

In general, certain embodiments of the present disclosure provide compositions or mechanisms for oral administration of caffeine via a functional nutraceutical confectionary composition. According to various embodiments, a nutraceutical confectionary composition is provided with a ratio of caffeine to L-theanine ranging from about 1:1 to about 1:2. In some embodiments, the ratio of caffeine to L-theanine is about 2:3. In various embodiments, the nutraceutical confectionary composition may provide caffeine in a range from about 5 mg to about 100 mg per serving. L-theanine may be provided in a range from about 5 mg to about 200 mg per serving. In some embodiments, caffeine may comprise about 0.8% to 10% by weight of the composition; and L-theanine may comprise about 1.2% to 20% by weight of the composition. In certain embodiments, the nutraceutical confectionary composition may comprise a chewing gum.

A composition for diet supplementation to improve gut microflora is disclosed. The composition includes a prebiotic source and source of nucleotides, such as an extract of yeast. Also disclosed are methods of diet supplementation that include administering compositions of the invention to an individual.

A composition for diet supplementation to improve gut microflora is disclosed. The composition includes a prebiotic source and source of nucleotides, such as an extract of yeast. Also disclosed are methods of diet supplementation that include administering compositions of the invention to an individual.